← All trials
NCT05868876
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2023
- Primary completion
- Nov 30, 2025
- Completion date
- Feb 28, 2026
- First posted
- May 22, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 205
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.